Taselisib Modestly Delays Progression in ER+ Breast Cancer

Bryant FurlowJun 2, 2018The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities.

Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news